Greg Zante insider trades: Viking Therapeutics (VKTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Greg reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | VKTX | ↓ Sell | 21,217 | $33.47 | $710K | Direct | Jul 29, 2026 (0d) |
| Jan 5, 2026 | VKTX | ↓ Sell | 57,661 | $32.90 | $1.9M | Direct | Jan 5, 2026 (0d) |
| Oct 28, 2025 | VKTX | ↓ Sell | 6,185 | $35.00 | $216K | Direct | Oct 28, 2025 (0d) |
| Jul 3, 2025 | VKTX | ↓ Sell | 4,266 | $27.76 | $118K | Direct | Jul 3, 2025 (0d) |
| Jan 6, 2025 | VKTX | ↓ Sell | 50,309 | $42.75 | $2.2M | Direct | Jan 6, 2025 (0d) |
| Oct 28, 2024 | VKTX | ↓ Sell | 131,687 | $76.61 | $10.1M | Direct | Oct 28, 2024 (0d) |
| Jul 30, 2024 | VKTX | ↓ Sell | 16,136 | $57.15 | $922K | Direct | Jul 31, 2024 (1d) |
| May 3, 2024 | VKTX | ↓ Sell | 66,756 | $74.69 | $5.0M | Direct | May 3, 2024 (0d) |
| Jan 4, 2024 | VKTX | ↓ Sell | 15,000 | $17.90 | $269K | Direct | Jan 4, 2024 (0d) |
| Apr 17, 2023 | VKTX | ↓ Sell | 7,500 | $20.00 | $150K | Direct | Apr 18, 2023 (1d) |
| Apr 12, 2023 | VKTX | ↓ Sell | 97,839 | $18.00 | $1.8M | Direct | Apr 13, 2023 (1d) |
| Apr 3, 2023 | VKTX | ↓ Sell | 161,940 | $17.19 | $2.8M | Direct | Apr 3, 2023 (0d) |
| Feb 14, 2008 | SGMO | ↓ Sell | 100 | $12.00 | $1K | Direct | Mar 12, 2008 (27d) |
| Feb 14, 2008 | SGMO | ↓ Sell | 5,000 | $12.02 | $60K | Direct | Feb 19, 2008 (5d) |
| Jan 8, 2008 | SGMO | ↓ Sell | 5,000 | $12.87 | $64K | Direct | Jan 10, 2008 (2d) |
| Dec 7, 2007 | SGMO | ↓ Sell | 5,000 | $15.80 | $79K | Direct | Dec 11, 2007 (4d) |
| Nov 8, 2007 | SGMO | ↓ Sell | 12,500 | $18.03 | $225K | Direct | Nov 13, 2007 (5d) |
| Dec 12, 2006 | SGMO | ↓ Sell | 39,917 | $7.02 | $280K | Direct | Dec 13, 2006 (1d) |
| Jun 1, 2006 | SGMO | ↓ Sell | 8,000 | $7.90 | $63K | Direct | Jun 5, 2006 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VKTX insiders
Open-market trades in the last 12 months
About Greg Zante's insider trades
Greg Zante is Chief Financial Officer at Viking Therapeutics (VKTX). Since Jun 1, 2006, Greg has reported no open-market purchases and 19 sales worth $26.8M on SEC Form 4. In the last 12 months: 2 sales ($2.6M).
Their filings also include grants and awards (18 filings), option exercises (12 filings), shares withheld for taxes (9 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VKTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.